Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-05-11 | Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist. He has wide-spread experience in pharmaceutical drug development; no mention of software or programming skills. |
| 2021-05-25 | Dr. Brughera has been CEO of Leadiant Biosciences SpA and held several positions for the Sigma-Tau Group, including CEO and Global Head Rare Disease and R&D at Sigma-tau; VP Preclinical Development at Nerviano Medical Sciences. He also served as Managing Director at Accelera, an independent contract research organization. |
| 2022-05-02 | Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist. He has wide-spread experience and knowledge of pharmaceutical drug development. |
| 2023-04-28 | Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist. Dr. Brughera has wide-spread experience and knowledge of pharmaceutical drug development in international companies. |
| 2024-05-13 | Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist. Dr. Brughera has wide-spread experience and knowledge of pharmaceutical drug development in international companies. His scientific and business knowledge in particular in the oncology and orphan drug space deepens the board’s collective qualifications, skills and experience. |
Data sourced from SEC filings. Last updated: 2026-02-03